Ontology highlight
ABSTRACT:
SUBMITTER: Glade Bender J
PROVIDER: S-EPMC3445751 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Glade Bender Julia J Blaney Susan M SM Borinstein Scott S Reid Joel M JM Baruchel Sylvain S Ahern Charlotte C Ingle Ashish M AM Yamashiro Darrell J DJ Chen Alice A Weigel Brenda B Adamson Peter C PC Park Julie R JR
Clinical cancer research : an official journal of the American Association for Cancer Research 20120712 18
<h4>Purpose</h4>Aflibercept is a novel decoy receptor that efficiently neutralizes circulating VEGF. A pediatric phase I trial was conducted to define the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of aflibercept.<h4>Experimental design</h4>Cohorts of three to six children with refractory solid tumors received aflibercept intravenously over 60 minutes every 14 days, at 2.0, 2.5, or 3.0 mg/kg/dose. PK sampling and analysis of peripheral blood biomarker ...[more]